Irinotecan in the treatment of colorectal cancer: clinical overview.

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Journal of Clinical Oncology

• Publication date

  2001-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2001.19.5.1501PMID 11230497
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors

  2004cited by this paper
• Phase II evaluation of topotecan in patients with advanced colorectal cancer. A Southwest Oncology Group trial (SWOG 9241)

  2004cited by this paper
• Randomized Phase II Study of Irinotecan Plus Mitomycin C vs. Oxaliplatin Plus Mitomycin C in Patients with Advanced Fluoropyrimidine/Leucovorin-Pretreated Colorectal Cancer

  2002cited by this paper
• A phase I study of irinotecan in pediatric patients: a pediatric oncology group study.

  2001cited by this paper
• Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.

  2000cited by this paper
• Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.

  2000cited by this paper
• Phase I and pharmacologic study of irinotecan administered as a 96-hour infusion weekly to adult cancer patients.

  2000cited by this paper
• Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer.

  2000cited by this paper
• Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure

  2000cited by this paper
• Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.

  2000cited by this paper
• Overexpression of Bax enhances antitumor activity of chemotherapeutic agents in human head and neck squamous cell carcinoma.

  2000cited by this paper
• The ATM protein is required for sustained activation of NF-κB following DNA damage

  1999cited by this paper
• Dimerization of mitochondrial Bax is associated with increased drug response in Bax-transfected A253 cells.

  1999cited by this paper
• CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR.

  1999cited by this paper
• Expression of DNA topoisomerase I and DNA topoisomerase II-alpha in carcinoma of the colon.

  1999cited by this paper
• Folinic acid (FA) and 5-fluorouracil (FU) alone or with irinotecan (CPT-11) for advanced colorectal cancer (ACC): Preliminary results of a randomized phase II trial

  1999cited by this paper
• Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU).

  1999cited by this paper
• Combined irinotecan and oxaliplatin plus granulocyte colony-stimulating factor in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectal cancer.

  1999cited by this paper
• Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children.

  1999cited by this paper
• Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumors.

  1999cited by this paper
• Combination of oxaliplatin plus irinotecan in patients with gastrointestinal tumors: results of two independent phase I studies with pharmacokinetics.

  1999cited by this paper
• Phase I and pharmacokinetic study of irinotecan administered as a low-dose, continuous intravenous infusion over 14 days in patients with malignant solid tumors.

  1999cited by this paper
• Sequence-dependent growth inhibition and DNA damage formation by the irinotecan-5-fluorouracil combination in human colon carcinoma cell lines.

  1999cited by this paper
• Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin.

  1999cited by this paper
• Phase I study of a weekly schedule of irinotecan, high-dose leucovorin, and infusional fluorouracil as first-line chemotherapy in patients with advanced colorectal cancer.

  1999cited by this paper
• A randomized phase II trial assessing irinotecan (IRI) and 5FU/folinic acid (LV), “Mayo regimen”, in first line palliative chemotherapy patients (pts) with metastatic colorectal cancer (MCRC)

  1999cited by this paper
• Involvement of cyclin d1‐cdk5 overexpression and mcm3 cleavage in bax‐associated spontaneous apoptosis and differentiation in an a253 human head and neck carcinoma xenograft model

  1999cited by this paper
• Reversal of MDR1-associated resistance to topotecan by PAK-200S, a new dihydropyridine analogue, in human cancer cell lines

  1999cited by this paper
• Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line.

  1999cited by this paper
• Concurrent irinotecan and 5-fluorouracil plus levo-folinic acid given every other week in the first-line management of advanced colorectal carcinoma: a phase I study of the Southern Italy Cooperative Oncology Group.

  1999cited by this paper
• Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells.

  1999cited by this paper
• CPT-11 in gastrointestinal cancer.

  1999cited by this paper
• Irinotecan combined with bolus fluorouracil, continuous infusion fluorouracil, and high-dose leucovorin every two weeks (LV5FU2 regimen): a clinical dose-finding and pharmacokinetic study in patients with pretreated metastatic colorectal cancer.

  1999cited by this paper
• New drugs in therapy of colorectal cancer: preclinical studies.

  1999cited by this paper
• A multicenter, Phase II trial of weekly irinotecan (CPT‐11) in patients with previously treated colorectal carcinoma

  1999cited by this paper
• Oxaliplatin: a new therapeutic option in colorectal cancer.

  1999cited by this paper
• High-dose topotecan with granulocyte-colony stimulating factor in fluoropyrimidine-refractory colorectal cancer: a phase II and pharmacodynamic study.

  1998cited by this paper
• Reversal of CPT-11 resistance of lung cancer cells by adenovirus-mediated gene transfer of the human carboxylesterase cDNA.

  1998cited by this paper
• A phase II study of irinotecan alternated with five days bolus of 5-fluorouracil and leucovorin in first-line chemotherapy of metastatic colorectal cancer.

  1998cited by this paper
• Inhibition of intestinal microflora β-glucuronidase modifies the distribution of the active metabolite of the antitumor agent, irinotecan hydrochloride (CPT-11) in rats

  1998cited by this paper
• Crystal structures of human topoisomerase I in covalent and noncovalent complexes with DNA.

  1998cited by this paper
• Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer.

  1998cited by this paper
• Cellular interactions of 5-fluorouracil and the camptothecin analogue CPT-11 (irinotecan) in a human colorectal carcinoma cell line.

  1998cited by this paper
• CPT-11 sensitivity in relation to the expression of P170-glycoprotein and multidrug resistance-associated protein.

  1998cited by this paper
• Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer.

  1998cited by this paper
• Recommended guidelines for the treatment of chemotherapy-induced diarrhea.

  1998cited by this paper
• A role for the amino terminus of human topoisomerase I.

  1998cited by this paper
• Reduced cellular accumulation of topotecan: a novel mechanism of resistance in a human ovarian cancer cell line.

  1998cited by this paper
• Camptothecins: a review of their development and schedules of administration.

  1998cited by this paper
• Interleukin 15 offers selective protection from irinotecan-induced intestinal toxicity in a preclinical animal model.

  1998cited by this paper
• Schedule-dependent synergism between raltitrexed and irinotecan in human colon cancer cells in vitro.

  1998cited by this paper
• Molecular modeling studies of the DNA-topoisomerase I ternary cleavable complex with camptothecin.

  1998cited by this paper
• Effect of adding the topoisomerase I poison 7-ethyl-10-hydroxycamptothecin (SN-38) to 5-fluorouracil and folinic acid in HCT-8 cells: elevated dTTP pools and enhanced cytotoxicity

  1998cited by this paper
• Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer.

  1998cited by this paper
• Combination of irinotecan (CPT11) and 5-fluorouracil with an analysis of cellular determinants of drug activity.

  1998cited by this paper
• Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme.

  1998cited by this paper
• A model for the mechanism of human topoisomerase I.

  1998cited by this paper
• Irinotecan (CPT-11) metabolism and disposition in cancer patients.

  1998cited by this paper
• The Role of Glucuronidation in 7‐Ethyl‐10‐hydroxycamptothecin Resistance in vitro

  1997cited by this paper
• Thymidylate synthase inhibitors in cancer therapy: direct and indirect inhibitors.

  1997cited by this paper
• Gene Mutation Analysis and Quantitation of DNA Topoisomerase I in Previously Untreated Non‐small Cell Lung Carcinomas

  1997cited by this paper
• Sequence‐dependent activity of the irinotecan‐5FU combination in human colon‐cancer model HT‐29 in vitro and in vivo

  1997cited by this paper
• Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy.

  1997cited by this paper
• CPT‐11 in human colon‐cancer cell lines and xenografts: Characterization of cellular sensitivity determinants

  1997cited by this paper
• Phase II trial of irinotecan in patients with metastatic colorectal carcinoma.

  1997cited by this paper
• Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients.

  1997cited by this paper
• Expression of the multidrug resistance-associated protein (MRP) gene in colorectal carcinomas.

  1997cited by this paper
• High dose-intensity of irinotecan administered every 3 weeks in advanced cancer patients: a feasibility study.

  1997cited by this paper
• Sequence-dependent activity of the irinotecan-5FU combination in human colon-cancer model HT-29 in vitro and in vivo.

  1997cited by this paper
• Phase I dose finding study of irinotecan (CPT-11) over a short i.v. infusion combined with a fixed dose of 5-fluorouracil (5-FU) protracted continuous i.v. infusion in patients with advanced solid tumours

  1997cited by this paper
• Topoisomerase I inhibitors: review and update.

  1997cited by this paper
• Ubiquitin-dependent Destruction of Topoisomerase I Is Stimulated by the Antitumor Drug Camptothecin*

  1997cited by this paper
• A comprehensive review of 5‐fluorouracil and leucovorin in patients with metastatic colorectal carcinoma

  1997cited by this paper
• Severe CPT-11 toxicity in patients with Gilbert's syndrome: two case reports.

  1997cited by this paper
• Pharmacokinetic interrelationships of irinotecan (CPT-11) and its three major plasma metabolites in patients enrolled in phase I/II trials.

  1997cited by this paper
• Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors.

  1996cited by this paper
• Variation in topoisomerase I gene copy number as a mechanism for intrinsic drug sensitivity.

  1996cited by this paper
• Involvement of beta-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats.

  1996cited by this paper
• No Alteration in DNA Topoisomerase I Gene Related to CPT‐11 Resistance in Human Lung Cancer

  1996cited by this paper
• The Multidrug Resistance‐associated Protein Gene Confers Drug Resistance in Human Gastric and Colon Cancers

  1996cited by this paper
• Conversion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38), by human liver carboxylesterase.

  1996cited by this paper
• Eukaryotic DNA topoisomerase I: genome gatekeeper and its intruders, camptothecins.

  1996cited by this paper
• Irinotecan is an active agent in untreated patients with metastatic colorectal cancer.

  1996cited by this paper
• Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer. Pharmacology and Molecular Mechanisms Group of the European Organization for Research and Treatment of Cancer.

  1996cited by this paper
• DNA topoisomerases.

  1996cited by this paper
• Modulation of DNA topoisomerase I activity by p53.

  1996cited by this paper
• Mechanism of Action of Camptothecin

  1996cited by this paper
• Preclinical evaluation of CPT-11 and its active metabolite SN-38.

  1996cited by this paper
• Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer.

  1996cited by this paper
• Irinotecan. A review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer.

  1996cited by this paper
• Mutation at the catalytic site of topoisomerase I in CEM/C2, a human leukemia cell line resistant to camptothecin.

  1995cited by this paper
• 700 Phase II study with topotecan (T) administered as a 21-days continuous infusion to patients with colorectal cancer

  1995cited by this paper
• Human immunodeficiency virus type 1 reverse transcriptase: enhancement of activity by interaction with cellular topoisomerase I.

  1995cited by this paper
• Topotecan in colorectal cancer: a phase II study of the EORTC early clinical trials group.

  1995cited by this paper
• Cross-resistance to camptothecin analogues in a mitoxantrone-resistant human breast carcinoma cell line is not due to DNA topoisomerase I alterations.

  1995cited by this paper
• Topoisomerase I-related parameters and camptothecin activity in the colon carcinoma cell lines from the National Cancer Institute anticancer screen.

  1995cited by this paper
• Characterisation of a human small-cell lung cancer cell line resistant to the DNA topoisomerase I-directed drug topotecan.

  1995cited by this paper
• The human topoisomerase I gene promoter is regulated by NF-IL6

  1995cited by this paper
• Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials.

  1995cited by this paper
• Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors.

  1995cited by this paper

• High-throughput screening of drug libraries identifies a new synergistic drug combination for the treatment of retinoblastoma.

  2026cites this paper
• Biosynthesis inspired asymmetric total synthesis of camptothecin.

  2025cites this paper
• Sequentially unlockable prodrug nanoparticles enable spatiotemporal coordination of chemotherapy and tumor microenvironment regulation for metastasis prevention in breast cancer.

  2025cites this paper
• Colorectal cancer epidemiology (1990–2050): lessons from the Australasian experience

  2025cites this paper
• Real-Time Visualization of Endogenous H2O2 Production in Mammalian Spheroids by Electrochemiluminescence

  2025cites this paper
• AI-Driven Discovery of Highly Specific and Efficacious hCES2A Inhibitors for Ameliorating Irinotecan-Triggered Gut Toxicity.

  2025cites this paper
• Colon cancer biology and treatment in the era of precision oncology: A primer for Radiologists.

  2025cites this paper
• Irinotecan's molecular mechanisms against cancer: a primary system biology and chemoinformatics approach for novel formulation development

  2025cites this paper
• Gastrointestinal cancer resistance to treatment: the role of microbiota

  2024cites this paper
• Raltitrexed Chemotherapy Regimen Plus Bevacizumab as Second-Line Treatment for Metastatic Colorectal Cancer: A Prospective Multicenter Phase II Trial

  2024cites this paper
• Gut microbiota modulation through Traditional Chinese Medicine (TCM) - improving outcomes in Gastrointestinal (GI) cancer prevention and management

  2024cites this paper
• Irinotecan-Induced Transient Dysarthria in a Patient With Metastatic Colorectal Cancer: A Case Report

  2024cites this paper
• Discovery of Indolo[3,2-c]isoquinoline Derivatives as Novel Top1/2 Dual Inhibitors with Orally Efficacious Antitumor Activity and Low Toxicity.

  2024cites this paper
• Organo-cation catalyzed enantioselective α-hydroxylation of pyridinone-fused lactones: asymmetric synthesis of SN-38 and irinotecan.

  2024cites this paper
• Evaluation of bioactive compounds, antioxidant and antimicrobial properties of Bulbophyllum griffithii (Lindl.) Rchb.f., an unexplored rare orchid of therapeutic importance

  2024cites this paper
• UGT1A1 Testing in Breast Cancer: should it become routine practice in patients treated with antibody-drug conjugates?

  2024cites this paper
• Population pharmacokinetics of intraperitoneal irinotecan and SN‐38 in patients with peritoneal metastases from colorectal origin

  2024cites this paper
• Irinotecan-loaded magnetite-silica core-shell systems for colorectal cancer treatment.

  2024cites this paper
• Inhibition of mitochondrial fission activates glycogen synthesis to support cell survival in colon cancer

  2023cites this paper
• Microbiota in cancer: molecular mechanisms and therapeutic interventions

  2023cites this paper
• Targeting the gut microbiota to alleviate chemotherapy-induced toxicity in cancer

  2023cites this paper
• Increased binding of anti-dsDNA antibodies to short oligonucleotides modified with topoisomerase I reveals a potential new enzyme function independent from DNA relaxation

  2023cites this paper
• Reversibly "Double Locked" Hydroxycamptothecin Prodrug Nanoparticles for Targeted Chemotherapy of Lung Cancer.

  2023cites this paper
• Exposure to Antineoplastic Drugs in Occupational Settings: A Systematic Review of Biological Monitoring Data

  2022cites this paper
• Gut Microbiota Modulation of Efficacy and Toxicity of Cancer Chemotherapy and Immunotherapy.

  2022cites this paper
• Impact of low- and high-risk operators handling irinotecan on the blood contamination of health care workers in oncology day care units

  2022cites this paper
• Cancer pharmacomicrobiomics: targeting microbiota to optimise cancer therapy outcomes

  2022cites this paper
• Gut microbiota: a potential target for improved cancer therapy

  2022cites this paper
• New Visions on Natural Products and Cancer Therapy: Autophagy and Related Regulatory Pathways

  2022influential citation
• Targeting MUCL1 protein inhibits cell proliferation and EMT by deregulating β-catenin and increases irinotecan sensitivity in colorectal cancer

  2022cites this paper
• Refractory mixed proliferative and membranous lupus nephritis treated with the topoisomerase I inhibitor irinotecan as add-on therapy

  2021influential citation
• Evolution of Resistance to Irinotecan in Cancer Cells Involves Generation of Topoisomerase-Guided Mutations in Non-Coding Genome That Reduce the Chances of DNA Breaks

  2021cites this paper
• Transition‐Metal‐Catalyzed Addition/Cyclization Reactions of the C−N Multiple Bonds Containing Species

  2021cites this paper
• A Network Pharmacology Study on the Molecular Mechanisms of FDY003 for Breast Cancer Treatment

  2021cites this paper
• Jujube Powder Enhances Cyclophosphamide Efficiency against Murine Colon Cancer by Enriching CD8+ T Cells While Inhibiting Eosinophilia

  2021cites this paper
• Pharmaceutical significance and recent developments in utilizing bacterial enzymes

  2021cites this paper
• The chemotherapeutic CX-5461 primarily targets TOP2B and exhibits selective activity in high-risk neuroblastoma

  2021cites this paper
• Role of the microbiome in systemic therapy for pancreatic ductal adenocarcinoma (Review)

  2021cites this paper
• Possible Protective Effects of high- versus low- dose of lutein in combination with irinotecan on Liver of Rats: Role of Oxidative Stress and Apoptosis

  2021cites this paper
• SN38 loaded nanostructured lipid carriers (NLCs); preparation and in vitro evaluations against glioblastoma

  2021cites this paper
• Parallel G-quadruplex Structures Increase Cellular Uptake and Cytotoxicity of 5-Fluoro-2′-deoxyuridine Oligomers in 5-Fluorouracil Resistant Cells

  2021cites this paper
• Current Knowledge About the Implication of Bacterial Microbiota in Human Health and Disease

  2021cites this paper
• One pot synthesis of some new N-allyl and N-benzyl quinazolinones and their anti-inflammatory activity

  2021cites this paper
• All You Need to Know About UGT1A1 Genetic Testing for Patients Treated With Irinotecan: A Practitioner-Friendly Guide.

  2021cites this paper
• Gut microbiota as a target to limit toxic effects of traditional Chinese medicine: Implications for therapy.

  2021cites this paper
• Enhanced Anti-Tumor Activity in Mice with Temozolomide-Resistant Human Glioblastoma Cell Line-Derived Xenograft Using SN-38-Incorporated Polymeric Microparticle

  2021cites this paper
• Does equipment change impact blood contamination with irinotecan and its two major metabolites in a centralized cytotoxic pharmacy unit?

  2020cites this paper
• Systems Pharmacology Study of the Anticervical Cancer Mechanisms of FDY003

  2020cites this paper
• Plant cell culture systems for the production of secondary metabolites : a review

  2020cites this paper
• The novel camptothecin derivative, CPT211, induces cell cycle arrest and apoptosis in models of human breast cancer.

  2020cites this paper
• Hyaluronic acid–doxorubicin nanoparticles for targeted treatment of colorectal cancer

  2020cites this paper
• Pharmacogenetic impact of UGT1A1 polymorphisms on pulmonary neuroendocrine tumours treated with metronomic irinotecan‐based chemotherapy in Chinese populations

  2020cites this paper
• Nanocrystalline ZnO: A Competent and Reusable Catalyst for the Preparation of Pharmacology Relevant Heterocycles in the Aqueous Medium

  2020cites this paper
• Novel Forms of Immunomodulation for Cancer Therapy.

  2020cites this paper
• Clinical Study Protocol

  2020cites this paper
• Targeting gut microbiota for precision medicine: Focusing on the efficacy and toxicity of drugs

  2020cites this paper
• Biologická charakteristika buněk kolorektálního karcinomu v modelech in vitro a její využití při individualizaci terapie

  2019cites this paper
• Mechanisms of gastrointestinal microflora on drug metabolism in clinical practice

  2019cites this paper
• Design and synthesis of novel sulphamide tethered quinazolinone hybrids as potential antitumor agents

  2019cites this paper
• Quantifying Risk Pathway Crosstalk Mediated by miRNA to Screen Precision drugs for Breast Cancer Patients

  2019cites this paper
• Intestinal bacterial β-glucuronidase as a possible predictive biomarker of irinotecan-induced diarrhea severity.

  2019cites this paper
• Current Practices and Awareness of Anticancer Plants in the Traditional Healthcare System

  2018cites this paper
• Pharmacometabolomic prediction of individual differences of gastrointestinal toxicity complicating myelosuppression in rats induced by irinotecan

  2018cites this paper
• Natural Product Synthesis for Drug Discovery and Chemical Biology

  2018cites this paper
• Food–drug interactions involving multiple mechanisms: A case study with effect of Capsaicin on the pharmacokinetics of Irinotecan and its main metabolites in rat

  2018cites this paper
• Fabrication of Ionic‐Liquid‐Embedded ZnO Nanoparticles: Application of a Synergistic Catalytic Effect to Thiol‐Induced 2‐Pyridone Synthesis

  2018cites this paper
• Visible-Light-Induced Radical Cascade Cyclization: Synthesis of (20S )-Camptothecin, SN-38 and Irinotecan

  2018cites this paper
• Targeted Triple Drug Regimen for the Treatment of Prostate Cancer

  2018cites this paper
• PLGA-PEG-RA-based polymeric micelles for tumor targeted delivery of irinotecan

  2018cites this paper
• DNA-based nanoscaffolds as vehicles for 5-fluoro-2'-deoxyuridine oligomers in colorectal cancer therapy.

  2018cites this paper
• Preclinical studies for the combination of paclitaxel and curcumin in cancer therapy (Review).

  2017cites this paper
• Biologics in bowel cancer.

  2017cites this paper
• Combined DPD and UGT1A1 Mutation in a Single Patient: A Case Report

  2017cites this paper
• Improved selectivity and cytotoxic effects of irinotecan via liposomal delivery: A comparative study on Hs68 and HeLa cells

  2017cites this paper
• Resveratrol-3-O-glucuronide and resveratrol-4'-O-glucuronide reduce DNA strand breakage but not apoptosis in Jurkat T cells treated with camptothecin.

  2017cites this paper
• Gut microbiota modulation of chemotherapy efficacy and toxicity

  2017cites this paper
• Solid lipid nanoparticles containing 7-ethyl-10-hydroxycamptothecin (SN38): Preparation, characterization, in vitro, and in vivo evaluations.

  2016cites this paper
• Pharmacokinetics and safety of DTS-108, a human oligopeptide bound to SN-38 with an esterase-sensitive cross-linker in patients with advanced malignancies: a Phase I study

  2016cites this paper
• DPYD*2A/*5A/*9A and UGT1A1*6/*28 polymorphisms in Chinese colorectal cancer patients.

  2016cites this paper
• GENETIC TRANSFORMATION OF CERATOTHECA TRILOBA FOR THE PRODUCTION OF ANTHRAQUINONES FROM HAIRY ROOT CULTURES

  2016cites this paper
• Quinazolinones-Phenylquinoxaline hybrids with unsaturation/saturation linkers as novel anti-proliferative agents.

  2016cites this paper
• Pharmacogenomics of Tamoxifen

  2016cites this paper
• Development of LC–MS/MS Method for Simultaneous Determination of Irinotecan and Its Main Metabolites in Rat Plasma, and Its Application in Pharmacokinetic Studies

  2016cites this paper
• Identification and characterization of naturally occurring inhibitors against human carboxylesterase 2 in White Mulberry Root-bark.

  2016cites this paper
• The influence of gut microbiota on drug metabolism and toxicity

  2016cites this paper
• ABCG2 expression in colorectal adenocarcinomas may predict resistance to irinotecan.

  2016cites this paper
• Enzyme/Prodrug Systems for Cancer Gene Therapy

  2016cites this paper
• Different schedules of irinotecan administration: A meta-analysis.

  2016cites this paper
• Cobalt-Catalyzed Dual Annulation of o-Halobenzaldimine with Alkyne: A Powerful Route toward Bioactive Indenoisoquinolinones.

  2015cites this paper
• Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer.

  2015cites this paper
• Gut Microbiota And Its Role In Drug Metabolism Of Common Drugs – A Short Review

  2015cites this paper
• Use of atropine-diphenoxylate compared with hyoscyamine to decrease rates of irinotecan-related cholinergic syndrome.

  2015cites this paper
• Luotonin-A based quinazolinones cause apoptosis and senescence via HDAC inhibition and activation of tumor suppressor proteins in HeLa cells.

  2015cites this paper
• Quantitative Determination of Irinotecan and the Metabolite SN-38 by Nanoflow Liquid Chromatography-Tandem Mass Spectrometry in Different Regions of Multicellular Tumor Spheroids

  2015cites this paper
• Fasting protects against the side effects of irinotecan but preserves its anti-tumor effect in Apc15lox mutant mice

  2015cites this paper
• The antioxidative and cytotoxic effects of hibiscus sabdariffa on mcf7 and mcf12a breast cell lines

  2015cites this paper
• Clinical Diagnosis and Therapy of Colorectal Cancer Chapter : Treatment of Colorectal Cancer Liver Metastases : Clinical and Molecular Aspects

  2015cites this paper
• Evaluation of mucositis induced by irinotecan after microbial colonization in germ-free mice.

  2015cites this paper
• Filled carbon nanotubes in biomedical imaging and drug delivery

  2015cites this paper
• Carboxylesterase 2 as a Determinant of Response to Irinotecan and Neoadjuvant FOLFIRINOX Therapy in Pancreatic Ductal Adenocarcinoma.

  2015cites this paper